Focus on genetic and epigenetic events of colorectal cancer pathogenesis: Implications for molecular diagnosis

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 6195-6206

  Zoratto, Federica ^a   Rossi, Luigi ^b   Verrico, Monica ^b   Papa, Anselmo ^b   Basso, Enrico ^c   Zullo, Angelo ^d   Tomao, Luigi ^e   Romiti, Adriana ^f   Russo, Giuseppe Lo ^b   Tomao, Silverio ^b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SAN CARLO HOSPITAL   (Italy)

^d NUOVO REGINA MARGHERITA HOSPITAL   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biomolecular markers; Colorectal cancer pathogenesis; Epigenetic events; Genetic events

Indexed keywords

APC PROTEIN; BIOLOGICAL MARKER; HISTONE; K RAS PROTEIN; MICRORNA; PROTEIN P53;

CANCER GENETICS; CANCER RISK; CANCER SCREENING; CANCER STEM CELL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; CPG ISLAND; CYTOGENETICS; DNA METHYLATION; DNA MODIFICATION; EARLY DIAGNOSIS; ENVIRONMENTAL FACTOR; EPIGENETICS; FAMILIAL CANCER; GENE INACTIVATION; GENE MUTATION; HETEROZYGOSITY LOSS; HUMAN; MICROSATELLITE INSTABILITY; MOLECULAR DIAGNOSIS; ONCOGENE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TUMOR SUPPRESSOR GENE;

CELL TRANSFORMATION, NEOPLASTIC; CHROMOSOMAL INSTABILITY; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; MICRORNAS; PATHOLOGY, MOLECULAR; TUMOR MARKERS, BIOLOGICAL;

EID: 84905005712     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1845-9     Document Type: Review

References (132)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Sengupta N, Gill KA, MacFie TS, Lai CS, Suraweera N, McDonald S, et al. Management of colorectal cancer: a role for genetics in prevention and treatment? Pathol Res Pract. 2008;204(7):469-77.
3. Migliore L, Migheli F, Spisni R, Coppedè F. Genetics, cytogenetics and epigenetics of colorectal cancer. J Biomed Biotechnol. 2011;2011:792362.
4. Kinzler KW, Vogelstein B. Cancer susceptibility genes. Gatekeepers and caretakers. Nature. 1997;386(6627):761-3.
5. Karen E. Kim; Early detection and prevention of colorectal cancer. Slack Incorporated 2009.
6. Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB. A review of the most promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist. 2010;15(7):699-731.
7. Kahng LS. Genetic aspects of non-polypoid colorectal neoplasms. Gastrointest Endosc Clin N Am. 2010;20(3):573-8.
8. Pancione M, Remo A, Colantuoni V. Genetic and epigenetic events generate multiple pathways in colorectal cancer progression. Pathol Res Int. 2012;2012:509348.
9. Worthley DL, Leggett BA. Colorectal cancer: molecular features and clinical opportunities. Clin Biochem Rev. 2010;31(2):31-8.
10. Costedio M, Church J. Pathways of carcinogenesis are reflected in patterns of polyp pathology in patients screened for colorectal cancer. Dis Colon Rectum. 2011;54(10):1224-8.
11. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011;6:479-507.
12. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759-67.
13. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138(6):2059-72.
14. Huang D, Du X. Crosstalk between tumor cells and microenvironment via Wnt pathway in colorectal cancer dissemination. World J Gastroenterol. 2008;14(12):1823-7. (Pubitemid 351523810)
15. Booth RA.Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett. 2007;249(1):87-96. (Pubitemid 46437280)
16. De Roock W, Biesmans B, De Schutter J, Tejpar S. Clinical biomarkers in oncology: focus on colorectal cancer. Mol Diag Ther. 2009;13(2):103-14.
17. Lievre A, Blons H, Laurent-Puig P. Oncogenic mutations as predictive factors in colorectal cancer. Oncogene. 2010;29(21):3033-43.
18. Douillard YJ, Oliner KS, Siena S, et al. N Engl J Med. 2013;369(11):1023-34.
19. Vogelstein B, Fearon ER, Hamilta SR, et al. N Engl J Med. 1988;319:525-32.
20. Deschoolmeester V, Baay M, Specenier P, Lardon F, Vermorken JB. A review of themost promising biomarkers in colorectal cancer: one step closer to targeted therapy. Oncologist. 2010;15(7):699-731.
21. Jen J, Kim H, Piantadosi S, et al. N Engl J Med. 1994;331:213-21.
22. Kanthan R, Senger AL, Kanthan C. Molecular events in primary and metastatic colorectal carcinoma: a review. Pathol Res Int. 2012;2012:597497.
23. Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2404-60.
24. Cahill DP, Lengauer C, Yu J, et al. Nature. 1998;392(6673):300-3.
25. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008;10(1):13-27. (Pubitemid 351184831)
26. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50(1):113-30. (Pubitemid 44953403)
27. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2009;31(1):27-36.
28. Esteller M. Molecular origins of cancer: epigenetics in cancer. N Engl J Med. 2008;358(11):1148-096.
29. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74.
30. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135(4):1079-99.
31. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138(6):2073-87.
32. Iacopetta B, Grieu F, Amanuel B. Microsatellite instability in colorectal cancer. Asia-Pac J Clin Oncol. 2010;6(4):260-9.
33. De la Chapelle A, Hampel H. Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol. 2010;28(20):3380-7.
34. De la Chapelle A. Microsatellite instability. N Engl J Med. 2003;349(3):209-2010.
35. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, et al. The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology. 2007;132(1):127-38. (Pubitemid 46108731)
36. Yim KL. Microsatellite instability in metastatic colorectal cancer: a review of pathology, response to chemotherapy and clinical outcome. Med Oncol. 2012;29(3):1796-801.
37. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer. Gastroenterology. 2008;135(4):1079-99.
38. Yamauchi M, Lochhead P, Morikawa T, Huttenhower C, Chan AT, Giovannucci E, et al. Colorectal cancer: a tale of two sides, or a continuum? Gut. 2012;61(6):794-7.
39. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med. 2009;60:167-79.
40. Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: translation of molecular biology into clinical application. Mol Cancer. 2009;8:102.
41. Goel A, Boland CR. Recent insights into the pathogenesis of colorectal cancer. Curr Opin Gastroenterol. 2010;26(1):47-52.
42. de Krijger I, Mekenkamp LJM, Punt CJA, Nagtegaal ID.MicroRNAs in colorectal cancer metastasis. J Pathol. 2011;224:438-47.
43. Yang L, Belaguli N, Berger DH. MicroRNA and colorectal cancer. World J Surg. 2009;33(4):638-46.
44. Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28(10):1057-68.
45. Wong JJL, Hawkins NJ, Ward RL. Colorectal cancer: a model for epigenetic tumorigenesis. Gut. 2007;56(1):140-8. (Pubitemid 46044900)
46. Venkatachalam R, Ligtenberg MJ, Hoogerbrugge N, de Bruijn DR, Kuiper RP. Geurts van Kessel, A. The epigenetics of (hereditary) colorectal cancer. Cancer Genet Cytogenet. 2010;203(1):1-6.
47. Kim YS, Deng G. Epigenetic changes (aberrant DNA methylation) in colorectal neoplasia. Gut Liver. 2007;1(1):1-11.
48. Ogino S, Hazra A, Tranah GJ, Kirkner GJ, Kawasaki T, Nosho K, et al. MGMT germline polymorphism is associated with somatic MGMT promoter methylation and gene silencing in colorectal cancer. Carcinogenesis. 2007;28(9):1985-90. (Pubitemid 47514483)
49. Raptis S, Mrkonjic M, Green RC, Pethe VV, Monga N, Chan YM, et al. MLH1-93G>A promoter polymorphism and the risk of microsatellite-unstable colorectal cancer. J Natl Cancer Inst. 2007;99(6):463-74. (Pubitemid 47078735)
50. SamowitzWS, Curtin K, Wolff RK, Albertsen H, Sweeney C, Caan BJ, et al. The MLH1-93 G>A promoter polymorphism and genetic and epigenetic alterations in colon cancer. Genes Chromosome Cancer. 2008;47(10):835-44.
51. Burgess DJ. Gene expression: colorectal cancer classification. Nat Rev Cancer. 2013;13(6):380-1.
52. Sadanandam A, Lyssiotis CA, Homicsko H, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med. 2013;19(5):619-25.
53. De Sosa E, Melo F, Wang X, Jansen M, et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med. 2013;19(5):614-8.
54. Ogino S, Stampfer M. Lifestyle factors and microsatellite instability in colorectal cancer: the evolving field of molecular pathological epidemiology. J Natl Cancer Inst. 2010;102(6):365-7.
55. Ogino S, Chan AT, Fuchs S, Giovannucci E. Molecular Pathologic epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2011;60(3):397-411.
56. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. CpG island methylator phenotype-low (CIMP-Low) in colorectal cancer: possible associations withmale sex and KRASmutations. JMol Diagn. 2006;8(5):582-8. (Pubitemid 44774157)
57. Hinoue T, Weisenberger JD, Lange CPE, Shen H, Byun HM, van den Berg D, et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 2012;22(2):271-82.
58. Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A. 2007;104(47):18654-9. (Pubitemid 350210752)
59. Issa JP. Methylation and prognosis: of molecular clocks and hypermethylator phenotypes. Clin Cancer Res. 2003;9(8):2879-81.
60. Shen L, Catalano PJ, Benson AB, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Cl in Cancer Res. 2007;13(20):6093 -8.
61. Minoo P, Baker K, Goswami R, Chong G, Foulkes WD, Ruszkiewicz AR, et al. Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut. 2006;55(10):1467-74. (Pubitemid 44476793)
62. Chirieac LR, Shen L, Catalano PJ, Issa JP, Hamilton SR. Phenotype of microsatellite-stable colorectal carcinomas with CpG island methylation. Am J Surg Pathol. 2005;29:429-36. (Pubitemid 40411172)
63. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011;42:1-10.
64. JaspersonKW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology. 2010;138:2044-58.
65. Gonzalez CA, Riboli E. Diet and cancer prevention: contributions from the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Eur J Cancer. 2010;46:2555-62.
66. Hiraoka S, Kato J, Fujiki S, Kaji E, Morikami T, Nawa T, et al. The presence of large serrated polyps increases risk for colorectal cancer. Gastroenterology. 2010;139:1503-10.
67. Hoffmeister M, Schmitz S, Karmrodt E, Stegmaier C, Haug U, Arndt V, et al. Male sex and smoking have a larger impact on the prevalence of colorectal neoplasia than family history of colorectal cancer. Clin Gastroenterol Hepatol. 2010;8:870-6.
68. Huang L, Wang X, Gong W, Huang Y, Jiang B. The comparison of the clinical manifestations and risk factors of colorectal cancer and adenomas: results from a colonoscopy-based study in southern Chinese. Int J Color Dis. 2010;25:1343-51.
69. Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer. 2006;119:2657-64. (Pubitemid 44691322)
70. Bretthauer M. Evidence for colorectal cancer screening. Best Pract Res Clin Gastroenterol. 2010;24:417-25.
71. Schernhammer ES, Giovannucci E, Kawasaki T, Rosner R, Fuchs CS, Ogino S. Dietary folate, alcohol, and B vitamins in relation to line-1 hypomethylation in colon cancer. Gut. 2010;59:794-9.
72. Dahm CC, Keogh RH, Spencer EA, Greenwood DC, Key TJ, Fentiman IS, et al. Dietary fiber and colorectal cancer risk: a nested case-control study using food diaries. J Natl Cancer Inst. 2010;102:614-26.
73. Hildebrand JS, Jacobs EJ, Campbell PT, McCullough ML, Teras LR, ThunMJ, et al. Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II. Cancer Epidemiol Biomarkers Prev. 2009;18:2835-41.
74. Kim DH, Smith-Warner SA, Spiegelman D, Yaun SS, Colditz GA, Freudenheim JL, et al. Pooled analyses of 13 prospective cohort studies on folate intake and colon cancer. Cancer Causes Control. 2010;21:1919-30.
75. Burt RW, Leppert MF, Slattery ML, Samowitz WS, Spirio LN, Kerber RA, et al. Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology. 2004;127:44-51.
76. Slattery ML, Curtin K, Sweeney C, Levin TR, Potter J, Wolff RK, et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer. 2007;120(3):656-63. (Pubitemid 44969038)
77. Satia JA, Keku T, Galanko JA, Martin C, Doctolero RT, Tajima A, et al. Diet, lifestyle, and genomic instability in the North Carolina Colon Cancer Study. Cancer Epidemiol Biomarkers Prev. 2005;14:429-36. (Pubitemid 40270108)
78. Campbell PT, Jacobs ET, Ulrich CM, Figueiredo JC, Poynter JN, McLaughlin JR, et al. Case-control study of overweight, obesity, and colorectal cancer risk, overall and by tumor microsatellite instability status. J Natl Cancer Inst. 2010;17:391-400.
79. Kuchiba A, Morikawa T, Yamauchi M, Imamura Y, Liao X, Chan AT, et al. Bodymass index and risk of colorectal cancer according to fatty acid synthase expression in the nurses' health study. J Natl Cancer Inst. 2012;104:415-20.
80. Morikawa T, Kuchiba A, Lochhead P, Nishihara R, Yamauchi M, Imamura Y, et al. Prospective analysis of body mass index, physical activity, and colorectal cancer risk associated with b-catenin (CTNNB1) status. Cancer Res. 2013;73(5):1600-10.
81. Samowitz WS, Albertsen H, Sweeney C, Herrick J, Caan BJ, Anderson KE, et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst. 2006;98(23):1731-8. (Pubitemid 44942711)
82. Limsui D, Vierkant RA, Tillmans LS, Wang AH, Weisenberger DJ, Laird PW, et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes. J Natl Cancer Inst. 2010;21(102):1012-22.
83. Nishihara R, Morikawa T, Kuchiba A, Lochhead P, Yamauchi M, Liao X, et al. A prospective study of duration of smoking cessation and colorectal cancer risk by epigenetics-related tumor classification. Am J Epidemiol. 2013;1(178):84-100.
84. Nishihara R, Lochhead P, Kuchiba A, Jung S, YamauchiM, Liao X, et al. Aspirin use and risk of colorectal cancer according to BRAF mutation status. JAMA. 2013;309(24):2563-71.
85. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131-42. (Pubitemid 47010839)
86. Rizzo A, Pallone F, Monteleone G, Fantini MC. Intestinal inflammation and colorectal cancer: a double-edged sword? World J Gastroenterol. 2011;17:3092-100.
87. Erreni M, Mantovani A, Allavena P. Tumor-associated macrophages (tam) and inflammation in colorectal cancer. Cancer Microenviron. 2011;4:141-54.
88. Mueller MM, Fusenig NE. Friends or foes-Bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004;4:839-49. (Pubitemid 39472951)
89. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48:526-35. (Pubitemid 32234798)
90. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228-33. (Pubitemid 20366527)
91. Curtin K, Slattery ML, Ulrich CM, Bigler J, Levin TR, Wolff RK, et al. Genetic polymorphisms in one-carbon metabolism: associations with CpG island methylator phenotype (CIMP) in colon cancer and the modifying effects of diet. Carcinogenesis. 2007;28(8):1672-9. (Pubitemid 47303944)
92. Keku T, Millikan R, Worley K, Winkel S, Eaton A, Biscoco L, et al. 5,10-Methylenetetrahydrofolate reductase codon 677 and 1298 polymorphisms and colon cancer in African Americans and whites. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1611-21. (Pubitemid 36020015)
93. Levine AJ, Siegmund KD, Ervin CM, Diep A, Lee ER, Frankl HD, et al. The methylenetetrahydrofolate reductase 677C→T polymorphism and distal colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev. 2000;9(7):657-63. (Pubitemid 30482695)
94. Yamaji T, Iwasaki M, Sasazuki S, Sakamoto H, Yoshida T, Tsugane S. Methionine synthase A2756G polymorphism interacts with alcohol and folate intake to influence the risk of colorectal adenoma. Cancer Epidemiol Biomarkers Prev. 2009;18(1):267-74.
95. Iacopetta B, Heyworth J, Girschik J, Grieu F, Clayforth C, Fritschi L. The MTHFR C677T and ΔDNMT3B C-149 T polymorphisms confer different risks for right- and left-sided colorectal cancer. Int J Cancer. 2009;125(1):84-90.
96. Mokarram P, Kumar K, Brim H, Naghibaldhossaini F, Saberi-froozi M, Nouraie M, et al. Distinct high-profile methylated genes in colorectal cancer. PLoS One. 2009;4(9):e7012.
97. Zeisel SH. Gene response elements, genetic polymorphisms and epigenetics influence the human dietary requirement for choline. IUBMB Life. 2007;59(6):380-7. (Pubitemid 47027115)
98. Van Engeland M, Weijenberg MP, Roemen GMJM, Brink M, De Bruine AP, Goldbohm RA, et al. Effects of dietary folate and alcohol intake on promoter methylation in sporadic colorectal cancer: the Netherlands cohort study on diet and cancer. Cancer Res. 2003;63(12):3133-7. (Pubitemid 36735864)
99. Hamid A, Kiran M, Rana S, Kaur J. Low folate transport across intestinal basolateral surface is associated with down-regulation of reduced folate carrier in in vivo model of folate malabsorption. IUBMB Life. 2009;61(3):236-43.
100. Paun BC, Kukuruga D, Jin Z, Mori Y, Cheng Y, Duncan M, et al. Relation between normal rectal methylation, smoking status, and the presence or absence of colorectal adenomas. Cancer. 2010;116(19):4495-501.
101. Slattery ML, Curtin K, Sweeney C, Levin TR, Potter J, Wolff RK, et al. Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer. 2007;120(3):656-63. (Pubitemid 44969038)
102. Hughes LAE, van den Brandt PA, de Bruïne AP, Wouters KA, Hulsmans S, Spiertz A, et al. Early life exposure to famine and colorectal cancer risk: a role for epigenetic mechanisms. PLoS One. 2009;4(11):e7951.
103. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet. 2009;76(1):1-18.
104. Plaschke J, Engel C, Kruger S, Holinski-Feder E, Pagenstecher C, Mangold E, et al. Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic msh6 germline mutations compared with families withMLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. J Clin Oncol. 2004;22:4486-94. (Pubitemid 41185114)
105. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349:247-57. (Pubitemid 36859476)
106. Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829-34. (Pubitemid 30243745)
107. Burn J. Aspirin prevents cancer in Lynch syndrome. Eur J Cancer. 2009;7:320-1.
108. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med. 2006;354:261-9. (Pubitemid 43113031)
109. Juhn E, Khachemoune A. Gardner syndrome: skin manifestations, differential diagnosis and management. Am J Clin Dermatol. 2010;11(2):117-22.
110. Nieuwenhuis MH, Vasen HF. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol. 2007;61:153-61. (Pubitemid 46073779)
111. McGarrity TJ, Amos C. Peutz-Jeghers syndrome: clinicopathology and molecular alterations. Cell Mol Life Sci. 2006;63(18):2135-44. (Pubitemid 44465687)
112. Calva D, Howe JR. Hamartomatous polyposis syndromes. Surg Clin N Am. 2008;88(4):779-817. (Pubitemid 352040755)
113. Kaemmerer E, Klaus C, Jeon MK, Gassler N. Molecular classification of colorectal carcinomas: the genotype to phenotype relation. World J Gastroenterol. 2013;19(45):8163-7.
114. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 2010;138:2088-100.
115. East JE, Saunders BP, Jass JR. Sporadic and syndromic hyperplastic polyps and serrated adenomas of the colon: classification, molecular genetics, natural history, and clinical management. Gastroenterol Clin N Am. 2008;37:25-46. (Pubitemid 351289032)
116. Fanali C, Lucchetti D, Farina M, Corbi M, Cufino V, Cittadini A, et al. Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives. World J Gastroenterol. 2014;20(4):923-42.
117. Winawer S, Fletcher R, Rex D, Bond J, Burt R, Ferrucci J, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003;124(2):544-60. (Pubitemid 36169269)
118. Osborn NK, Ahlquist DA. Stool screening for colorectal cancer: molecular approaches. Gastroenterology. 2005;128(1):192-206. (Pubitemid 40039970)
119. Hardcastle JD, Thomas WM, Chamberlain J, Pye G, Sheffield J, James PD, et al. Randomised, controlled trial of faecal occult blood screening for colorectal cancer: results for first 107,349 subjects. Lancet. 1989;1(8648):1160-4. (Pubitemid 19138850)
120. Brenner DE, Rennert G. Fecal DNA biomarkers for the detection of colorectal neoplasia: attractive, but is it feasible? J Natl Cancer Inst. 2005;97(15):1107-9. (Pubitemid 41511203)
121. Creeden J, Junker F, Vogel-Ziebolz S, Rex D. Serum tests for colorectal cancer screening. Mol Diagn Ther. 2011;15(3):129-41.
122. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 2010;29(1):181-206.
123. Wong JJL, Hawkins NJ, Ward RL, Hitchins MP. Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer. Mod Pathol. 2011;24(3):396-411.
124. Dong SM, Traverso G, Johnson C, et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst. 2001;93:851-65.
125. Alquist DA, Skoletsky JE, Boynton KA, et al. Colorectal cancer screening]by detection of altered human DNA in stool; feasibility of a mutitarget assay panel. Gastroenterology. 2000;119:1219-27.
126. Calistri D, Rengucci C, Bocchini R, et al. Fecal multiple molecular tests to detect colorectal cancer in stool. Clin Gastroenterol Hepatol. 2003;1:377-83. (Pubitemid 37248057)
127. Roperch JP, Incitti R, Forbin F, et al. Aberrant methylation of NPY, PENK, and WIF1 as a promising marker for blood-based diagnosis of colorectal cancer. BMC Cancer. 2013;13:566.
128. Madhavan D, Cuk K, Burwinkel B, Yang R. Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. Front Genet. 2013;4:116.
129. Toiyama Y, Takahashi M, Hur K, et al. Serum miR-21 as a diagnostic and prognostic biomarker in colorectal cancer. J Natl Cancer Inst. 2013;105(12):849-59.
130. Kim MS, Lee J, Sidransky D. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev. 2010;29(1):181-206.
131. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 2008;135(4):1079-99.
132. Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007;50(1):113-30. (Pubitemid 44953403)